Immunotherapy, using a patient's genetically altered T-cells as a cancer treatment, may hold promise for some. Recent research indicates that the expensive process can slow, halt or seemingly cure metastatic cancer in some patients. Using a BiTE antibody, created by Maryland-based Micromet, may hold even more promise for immunotherapy by attaching to both the cancer cell and the T-cell and telling the T-cell to attack. Seven patients who received the therapy have experienced either a complete or partial response.
Published in Brief: